Sculptor Capital’s Protalix BioTherapeutics PLX Stock Holding History

Sculptor Capital’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-37,000	Closed	-$65.9K	–	397
2023 Q4	$65.9K	Hold	37,000	–	–	﹤0.01%	254
2023 Q3	$61.4K	Hold	37,000	–	–	﹤0.01%	271
2023 Q2	$74K	Buy	37,000 +17,900	+94%	+$42.6K	﹤0.01%	265
2023 Q1	$40.1K	Buy	+19,100	New	+$33.5K	﹤0.01%	363

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Sculptor Capital's PLX Position: Q1 2024 in Review

Sculptor Capital sold out of Protalix BioTherapeutics (PLX) in Q1 2024, closing a stake of 37,000 shares — an estimated $65.9K sold.

Sculptor Capital first reported a position in PLX in Q1 2023 and held it in 4 quarters. The position peaked at $74K in Q2 2023. 63 funds tracked by Wall St. Rank hold PLX as of Q1 2024.

Sculptor Capital reported no remaining Protalix BioTherapeutics position as of Q1 2024 after selling out during the quarter.
Sculptor Capital sold 37,000 Protalix BioTherapeutics shares in Q1 2024, an estimated $65.9K.
Sculptor Capital first reported a position in Protalix BioTherapeutics in Q1 2023 and held it in 4 quarters.
Sculptor Capital's Protalix BioTherapeutics position peaked at $74K in Q2 2023.
63 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2024.

Based on Sculptor Capital's 13F filing for Q1 2024, filed 15 May 2024.